文献速递血栓与止血

华法林对比低分子肝素治疗癌症相关血栓的总生存期

Overall survival with warfarin vs. low-molecular-weight heparin in cancer-associated thrombosis.
PubMed 文献 · J Thromb Haemost · 2021-09-21

基于SEER-Medicare数据库2007至2016年数据,纳入9706例66岁以上、诊断胃癌、结直肠癌、胰腺癌、肺癌、卵巢癌或脑癌且发生癌症相关静脉血栓栓塞并30天内使用低分子肝素或华法林的患者。经匹配后分析显示,华法林组中位总生存期9.8个月,低分子肝素组7.2个月,华法林与更好的总生存期相关。

要点

  • 生存差异在癌症分期、年龄、合并症负担及VTE年份各亚组中一致。

核心结论

  • 在癌症相关静脉血栓栓塞治疗中,华法林相比低分子肝素与改善的总生存期相关。

研究设计与样本

  • 基于SEER-Medicare关联数据库2007至2016年的回顾性人群队列研究,纳入9706例66岁以上特定癌症合并VTE并30天内使用LMWH或华法林的患者。
  • 采用癌症分期精确匹配和倾向评分匹配(癌症诊断、年龄、VTE年份、癌症诊断至索引VTE时间)1:1匹配,Cox比例风险回归估计HR和95%CI。

主要发现

  • 生存差异在癌症分期、年龄、合并症负担及VTE年份各亚组中一致。

临床怎么用

  • 对于特定癌症(胃癌、结直肠癌、胰腺癌、肺癌、卵巢癌或脑癌)合并VTE的老年患者,华法林可能作为低分子肝素之外的治疗选择,但需结合出血风险个体化决策。

局限性

  • 回顾性观察性设计可能存在残余混杂,且仅纳入66岁以上Medicare参保人群,外推性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: When compared with warfarin, low-molecular-weight heparin (LMWH) reduces the incidence of recurrent venous thromboembolism (VTE) in cancer. However, a survival benefit of LMWH over warfarin for the treatment of cancer-associated VTE has not been established. METHODS: Using the Surveillance, Epidemiology and End Results and Medicare linked database from 2007 through 2016, we identified Medicare beneficiaries (aged ≥66 years) who were: (1) diagnosed with primary gastric, colorectal, pancreatic, lung, ovarian, or brain cancer; (2) diagnosed with cancer-associated VTE; and (3) prescribed LMWH or warfarin within 30 days. The primary outcome was overall survival (OS). Patients were matched 1:1 using exact matching for cancer stage and propensity score matching for cancer diagnosis, age, year of VTE, and time from cancer diagnosis to index VTE. Cox proportional-hazards regression was performed to estimate hazard ratios (HR) and 95% confidence intervals (95% CI). RESULTS: A total of 9706 patients were included. Warfarin was associated with a significant improvement in OS compared with LMWH (median OS, 9.8 months [95% CI, 9.1-10.4] vs. 7.2 months [95% CI, 6.8-7.8]; HR, 0.86; 95% CI 0.83-0.90; p < .001). The survival advantage was most pronounced in pancreatic (HR 0.82 [95% CI, 0.74-0.90], p < .001) and gastric cancers (HR 0.82 [95% CI, 0.68-0.98], p = .03). The observed differences in survival were consistent across subgroups including cancer stage, age, comorbidity burden, and year of VTE. CONCLUSIONS: In this population-based study, warfarin was associated with improved OS compared with LMWH for the treatment of cancer-associated VTE.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Chiasakul T, Redd R, Patell R, et al. Overall survival with warfarin vs. low-molecular-weight heparin in cancer-associated thrombosis. J Thromb Haemost. 2021. PMID: 34490999. doi:10.1111/jth.15519

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。